The Story
A lab accident turns transgenic mice into sharper learners. Within months the FDA clears it under a new 'innovation acceleration' framework that skips Phase III trials.
Three cognitive-enhancement drugs — AlphaAxon, BrainBatter, and Claricore — hit the market, each facing a one-year review that could pull it back off the shelves.
Congress is in chaos. The EU threatens sanctions. China denies any interest while quietly filing patents. Every neuroscientist, journalist, and fund manager has an agenda.
The fate of human cognition won't be settled by peer review — but by the people who know, the people who are loud, and the people who are rich. Which are you?
